Meditrina

Website Links

Description

President and Chief Executive Officer Thomas A. Collet is president and chief executive officer of Meditrina Pharmaceuticals, Incorporated and a co-founder of the Company. Prior to Meditrina, Thomas served as president and CEO of three early-stage life science companies where he was instrumental in creating, building and raising the first institutional funds. The companies were: Rubicon Genomics, Incorporated, a drug discovery and development tools and biomarker discovery company; ProNAi Therapeutics, Incorporated, a cancer therapeutics company; and, Neural Intervention Technologies, Incorporated (NIT), a medical device company developing a therapy for the treatment of hemorrhagic stroke. Previously, he was a general partner at Tullis-Dickerson (TD), where he managed its $40 million seed and early stage fund. Prior to his tenure at TD, Thomas was vice president, business development at Monsanto where he helped start Integrated Protein Technologies, the Company’s internal venture for the production of pharmaceutical proteins in green plants. Thomas started his career with McKinsey & Company, Inc, where he advised clients in Europe and in the United States on strategy and operations in the healthcare and pharmaceutical industries. At McKinsey & Company, his clients were primarily small, fast-growing, and technology-focused business units of Fortune 100 companies. Cumulatively, Thomas’ companies have raised more than $25 million in seed and early-stage capital since 2001 from venture capitalists, pharmaceutical companies, individual investors and government programs. Of particular note, NIT, which was supported by the State of Michigan Technology Tri-Corridor, was sold to W.L. Gore in 2006, generating the then largest cash return for this program since its inception in 2000. Thomas received his doctorate in biochemistry from the Massachusetts Institute of Technology, Cambridge, Massachusetts, and also conducted post-doctoral research at The Scripps Research Institute in La Jolla, California. He is fluent in English and German. Vice President, Clinical Development James Symons is vice president, clinical development at Meditrina Pharmaceuticals, Incorporated, and is responsible for the management of the Company’s clinical programs. Prior to joining Meditrina, Jim was a member of the research faculty of the Epidemiology Department in the School of Public Health at the University of Michigan where he conducted and analyzed studies from data collected in large, longitudinal programs. He began his clinical career at Parke-Davis with responsibilities increasing from clinical scientist to senior director until his retirement from Pfizer in 2005. While at Parke-Davis and Pfizer, Jim had primary responsibility for a number of drug development programs that resulted in NDA approvals. These included: femhrt

Products & services

Similar companies nearby